Sotorasib

Overview

Sotorasib is an oral, small molecule inhibitor targeting the G12C mutant of the KRAS protein, which is present in various types of cancers. It is used primarily in the treatment of non-small cell lung cancer (NSCLC) with specific KRAS mutations.

Patent & exclusivity (US)

Per the FDA Orange Book (3 approved US products), the latest listed US patent on Sotorasib expires 14 Sept 2040 and exclusivity 16 Jan 2032. Generic API sourcing typically opens up once these lapse.

Therapeutic areas